Hi Eyeswideopen,
Join this dot: (mesoblast's announcement on December 17)
"The DSMB reported that there were no safety concerns and noted that the trial is not likely to meet the 30-day mortality reduction endpoint at the planned 300 patient enrolment"
In other words, its unlikely to meet its objective.
with this dot: (my previous post)
'The term 'futility' is used to refer to the inability of a clinical trial to achieve its objective'
Clearly the objective of the trial was to meet a 30-day mortality endpoint but the DSMB have indicated that the trial was unlikely to meet that objective.
Where's the ambiguity?
I also don't like the fact that the trial is being wound up due to 'futility' but it doesn't change the fact.
- Forums
- ASX - By Stock
- MSB
- COVID-19 USA Daily Numbers
COVID-19 USA Daily Numbers, page-354
-
- There are more pages in this discussion • 322 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
97.0¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.107B |
Open | High | Low | Value | Volume |
98.5¢ | 98.5¢ | 96.0¢ | $2.168M | 2.226M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16000 | 96.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.0¢ | 86854 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16000 | 0.965 |
1 | 23000 | 0.960 |
8 | 163220 | 0.955 |
8 | 87646 | 0.950 |
3 | 82684 | 0.945 |
Price($) | Vol. | No. |
---|---|---|
0.970 | 86854 | 7 |
0.975 | 37184 | 2 |
0.980 | 44810 | 6 |
0.985 | 88504 | 4 |
0.990 | 54328 | 5 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online